SciELO - Scientific Electronic Library Online

 
vol.19 issue3Epidemiologic surveillance of measles and rubella in Campinas (SP), Brazil: the reliability of the dataGenomic risk and personal responsibility in health author indexsubject indexarticles search
Home Page  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista Panamericana de Salud Pública

On-line version ISSN 1680-5348Print version ISSN 1020-4989

Abstract

TREGNAGHI, Miguel et al. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America. Rev Panam Salud Publica [online]. 2006, vol.19, n.3, pp.179-188. ISSN 1680-5348.  http://dx.doi.org/10.1590/S1020-49892006000300006.

OBJECTIVES: In 1998 the World Health Organization (WHO) recommended the inclusion of Haemophilus influenza type B (Hib) conjugate vaccines in infant immunization programs, whenever in accordance with national priorities. GlaxoSmithKline Biologicals has developed a new pentavalent combined diphtheria-tetanus-whole cell pertussis-hepatitis B/Hib (DTPwHB/Hib) vaccine containing 5 µg of polyribosylribitol phosphate (PRP), and we assessed the immunogenicity and reactogenicity of primary and booster vaccination of healthy children with this new vaccine compared with a reference regimen consisting of the licensed DTPw-HB (Tritanrix) and Hib (Hiberix) vaccines given as simultaneous concomitant injections. METHODS: We performed a randomized, double-blind study from September 1998 to August 1999 to establish the immunogenicity and reactogenicity of primary and booster vaccination of healthy children with the new pentavalent combined DTPw-HB/Hib vaccine given as a single injection, compared with the reference regimen. RESULTS: Both vaccination regimens elicited excellent immune responses, with all subjects in both groups achieving seroprotective anti-PRP antibody concentrations of > 0.15 µg/mL one month after primary vaccination. The combined DTPw-HB/Hib vaccine was non-inferior to the licensed vaccines in terms of seroprotection/seropositivity/vaccine response rates for all antigen components. Persistence of antibodies against all study vaccine antigens up to the time of booster vaccination was comparable between groups, and a marked increase of all antibody concentrations was observed after the booster dose. Both vaccine regimens were similar in terms of their overall reactogenicity profiles. CONCLUSIONS: Our results indicate that the new DTPw-HB/Hib pentavalent combination vaccine provides an efficient and reliable way of implementing WHO recommendations for controlling hepatitis B and Hib infections on a worldwide basis.

Keywords : Vaccines [combined]; diphtheria-tetanus-pertussis vaccine; hepatitis B vaccines; Haemophilus vaccines; Latin America.

        · abstract in Spanish     · text in English     · English ( pdf )